STRO-227 / Sutro Biopharma - LARVOL DELTA

Sutro Biopharma Highlights Next-Generation ADC Innovation at Virtual R&D Day (GlobeNewswire) - "The presentation will include an overview of Sutro’s near- and long-term priorities, beginning with STRO-004, its potential best-in-class Tissue Factor ADC, which has now entered clinical development. The Company will also provide details on its dual-payload ADC programs, uniquely enabled by its proprietary cell-free platform, and reveal STRO-227, its first dual-payload candidate designed to target PTK7."

Clinical • New molecule • Solid Tumor